CHITA – a registry of in vitro NAMs
Where are we with validation of assays to replace animals for product testing? The short answer: not very far. While many innovative platforms with potential as animal alternatives have been…
Has FDA lost it’s way with NAMs? NAMs or New Alternative Methodologies is the term used by FDA for new regulatory tools to improve predictivity and help replace, reduce and/or…
Is coronavirus morbidity exacerbated by environmental pollution? A potential mechanism underlying thrombosis-related side effects connects multiple known risk factors. In the early days of the COVID-19 pandemic, signs that infected…
VCAM-1 is one of our favorite biomarkers. The levels of this clinical biomarker are increased in patients with diseases as diverse as Parkinson’s disease and arthritis. The regulation of VCAM-1…
